Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Effect of cholesterol and ergosterol on the antibiotic amphotericin B interactions with dipalmitoylphosphatidylcholine monolayers: X-ray reflectivity study.

Biochimica et biophysica acta

Kamiński DM, Czernel G, Murphy B, Runge B, Magnussen OM, Gagoś M.
PMID: 25128151
Biochim Biophys Acta. 2014 Nov;1838(11):2947-53. doi: 10.1016/j.bbamem.2014.08.004. Epub 2014 Aug 12.

Amphotericin B is a Streptomyces nodosus metabolite and one of the oldest polyene antibiotics used in the treatment of invasive systemic fungal infections. Despite its over 50-year existence in clinical practice and the recognition of amphotericin B as the...

Cite
Kamiński DM, Czernel G, Murphy B, et al. Effect of cholesterol and ergosterol on the antibiotic amphotericin B interactions with dipalmitoylphosphatidylcholine monolayers: X-ray reflectivity study. Biochim Biophys Acta. 2014;1838(11):2947-53doi: 10.1016/j.bbamem.2014.08.004.
Kamiński, D. M., Czernel, G., Murphy, B., Runge, B., Magnussen, O. M., & Gagoś, M. (2014). Effect of cholesterol and ergosterol on the antibiotic amphotericin B interactions with dipalmitoylphosphatidylcholine monolayers: X-ray reflectivity study. Biochimica et biophysica acta, 1838(11), 2947-53. https://doi.org/10.1016/j.bbamem.2014.08.004
Kamiński, Daniel M, et al. "Effect of cholesterol and ergosterol on the antibiotic amphotericin B interactions with dipalmitoylphosphatidylcholine monolayers: X-ray reflectivity study." Biochimica et biophysica acta vol. 1838,11 (2014): 2947-53. doi: https://doi.org/10.1016/j.bbamem.2014.08.004
Kamiński DM, Czernel G, Murphy B, Runge B, Magnussen OM, Gagoś M. Effect of cholesterol and ergosterol on the antibiotic amphotericin B interactions with dipalmitoylphosphatidylcholine monolayers: X-ray reflectivity study. Biochim Biophys Acta. 2014 Nov;1838(11):2947-53. doi: 10.1016/j.bbamem.2014.08.004. Epub 2014 Aug 12. PMID: 25128151.
Copy Download .nbib Format: NLM
Day-case stapes surgery: Day-case versus inpatient stapes surgery for otosclerosis: a randomized controlled trial.

BMC ear, nose, and throat disorders

Derks LSM, Wegner I, Tange RA, Kamalski DMA, Grolman W.
PMID: 26924941
BMC Ear Nose Throat Disord. 2016 Feb 27;16:3. doi: 10.1186/s12901-016-0024-6. eCollection 2016.

BACKGROUND: Otosclerosis is characterized by bony deposits in the otic capsule, resulting in stapes fixation and progressive hearing loss. It can be treated effectively by surgically removing (part of) the stapes and replacing it with a prosthesis. Increasingly, stapes...

Cite
Derks LSM, Wegner I, Tange RA, et al. Day-case stapes surgery: Day-case versus inpatient stapes surgery for otosclerosis: a randomized controlled trial. BMC Ear Nose Throat Disord. 2016;16:3doi: 10.1186/s12901-016-0024-6.
Derks, L. S. M., Wegner, I., Tange, R. A., Kamalski, D. M. A., & Grolman, W. (2016). Day-case stapes surgery: Day-case versus inpatient stapes surgery for otosclerosis: a randomized controlled trial. BMC ear, nose, and throat disorders, 163. https://doi.org/10.1186/s12901-016-0024-6
Derks, Laura S M, et al. "Day-case stapes surgery: Day-case versus inpatient stapes surgery for otosclerosis: a randomized controlled trial." BMC ear, nose, and throat disorders vol. 16 (2016): 3. doi: https://doi.org/10.1186/s12901-016-0024-6
Derks LSM, Wegner I, Tange RA, Kamalski DMA, Grolman W. Day-case stapes surgery: Day-case versus inpatient stapes surgery for otosclerosis: a randomized controlled trial. BMC Ear Nose Throat Disord. 2016 Feb 27;16:3. doi: 10.1186/s12901-016-0024-6. eCollection 2016. PMID: 26924941; PMCID: PMC4769570.
Copy Download .nbib Format: NLM
Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy.

Cancers

Zaborowska-Szmit M, Olszyna-Serementa M, Kowalski DM, Szmit S, Krzakowski M.
PMID: 34572760
Cancers (Basel). 2021 Sep 09;13(18). doi: 10.3390/cancers13184534.

Concurrent chemoradiotherapy is recommended for locally advanced and unresectable non-small-cell lung cancer (NSCLC), but radiotherapy alone may be used in patients that are ineligible for combined-modality therapy due to poor performance status or comorbidities, which may concern elderly patients...

Cite
Zaborowska-Szmit M, Olszyna-Serementa M, Kowalski DM, et al. Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184534.
Zaborowska-Szmit, M., Olszyna-Serementa, M., Kowalski, D. M., Szmit, S., & Krzakowski, M. (2021). Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. Cancers, 13(18), . https://doi.org/10.3390/cancers13184534
Zaborowska-Szmit, Magdalena, et al. "Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184534
Zaborowska-Szmit M, Olszyna-Serementa M, Kowalski DM, Szmit S, Krzakowski M. Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. Cancers (Basel). 2021 Sep 09;13(18). doi: 10.3390/cancers13184534. PMID: 34572760; PMCID: PMC8466795.
Copy Download .nbib Format: NLM
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Journal of clinical medicine

Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S.
PMID: 32349387
J Clin Med. 2020 Apr 27;9(5). doi: 10.3390/jcm9051268.

Cardiovascular diseases may determine therapy outcomes of non-small-cell lung cancer (NSCLC). The evidence for how iatrogenic cardiovascular complications contribute to ceasing anticancer treatment, decreasing the quality of life or even premature death, is unclear. Older patients and smokers are...

Cite
Zaborowska-Szmit M, Krzakowski M, Kowalski DM, et al. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 2020;9(5)doi: 10.3390/jcm9051268.
Zaborowska-Szmit, M., Krzakowski, M., Kowalski, D. M., & Szmit, S. (2020). Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. Journal of clinical medicine, 9(5), . https://doi.org/10.3390/jcm9051268
Zaborowska-Szmit, Magdalena, et al. "Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer." Journal of clinical medicine vol. 9,5 (2020). doi: https://doi.org/10.3390/jcm9051268
Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 2020 Apr 27;9(5). doi: 10.3390/jcm9051268. PMID: 32349387; PMCID: PMC7287714.
Copy Download .nbib Format: NLM
Individual applicator for brachytherapy for various sites of superficial malignant lesions.

Journal of contemporary brachytherapy

Kowalik L, Lyczek J, Sawicki M, Kazalski D.
PMID: 23634155
J Contemp Brachytherapy. 2013 Mar;5(1):45-9. doi: 10.5114/jcb.2013.34340. Epub 2013 Mar 29.

The aim of this paper is to discuss brachytherapy treatment and individual applicators suitable for unfavorably localized superficial malignant lesions. Techniques for manufacturing an individual applicator and clinical examples of its use for various locations of cancer are presented....

Cite
Kowalik L, Lyczek J, Sawicki M, et al. Individual applicator for brachytherapy for various sites of superficial malignant lesions. J Contemp Brachytherapy. 2013;5(1):45-9doi: 10.5114/jcb.2013.34340.
Kowalik, L., Lyczek, J., Sawicki, M., & Kazalski, D. (2013). Individual applicator for brachytherapy for various sites of superficial malignant lesions. Journal of contemporary brachytherapy, 5(1), 45-9. https://doi.org/10.5114/jcb.2013.34340
Kowalik, Lukasz, et al. "Individual applicator for brachytherapy for various sites of superficial malignant lesions." Journal of contemporary brachytherapy vol. 5,1 (2013): 45-9. doi: https://doi.org/10.5114/jcb.2013.34340
Kowalik L, Lyczek J, Sawicki M, Kazalski D. Individual applicator for brachytherapy for various sites of superficial malignant lesions. J Contemp Brachytherapy. 2013 Mar;5(1):45-9. doi: 10.5114/jcb.2013.34340. Epub 2013 Mar 29. PMID: 23634155; PMCID: PMC3635046.
Copy Download .nbib Format: NLM
Thickness-dependent ordering of water layers at the NaCl(100) surface.

The Journal of chemical physics

Arsic J, Kaminski DM, Radenovic N, Poodt P, Graswinckel WS, Cuppen HM, Vlieg E.
PMID: 15267987
J Chem Phys. 2004 May 22;120(20):9720-4. doi: 10.1063/1.1712971.

We have determined the ordering properties of water adsorbed at room temperature on the rock salt (100) surface under four different conditions: ultrahigh vacuum, dry nitrogen atmosphere, 45% and 75% relative humidity. Details of the atomic structure are determined...

Cite
Arsic J, Kaminski DM, Radenovic N, et al. Thickness-dependent ordering of water layers at the NaCl(100) surface. J Chem Phys. 2004;120(20):9720-4doi: 10.1063/1.1712971.
Arsic, J., Kaminski, D. M., Radenovic, N., Poodt, P., Graswinckel, W. S., Cuppen, H. M., & Vlieg, E. (2004). Thickness-dependent ordering of water layers at the NaCl(100) surface. The Journal of chemical physics, 120(20), 9720-4. https://doi.org/10.1063/1.1712971
Arsic, J, et al. "Thickness-dependent ordering of water layers at the NaCl(100) surface." The Journal of chemical physics vol. 120,20 (2004): 9720-4. doi: https://doi.org/10.1063/1.1712971
Arsic J, Kaminski DM, Radenovic N, Poodt P, Graswinckel WS, Cuppen HM, Vlieg E. Thickness-dependent ordering of water layers at the NaCl(100) surface. J Chem Phys. 2004 May 22;120(20):9720-4. doi: 10.1063/1.1712971. PMID: 15267987.
Copy Download .nbib Format: NLM
Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland.

Contemporary oncology (Poznan, Poland)

Kowalski DM, Krzakowski M, Ramlau R, Jaskiewicz P, Janowicz-Żebrowska A.
PMID: 23788872
Contemp Oncol (Pozn). 2012;16(2):170-5. doi: 10.5114/wo.2012.28798. Epub 2012 May 29.

AIM OF THE STUDY: Erlotinib and gefitinib are reversible EGFR-TKI administered orally. Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. We analyze efficacy of treatment...

Cite
Kowalski DM, Krzakowski M, Ramlau R, et al. Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Contemp Oncol (Pozn). 2012;16(2):170-5doi: 10.5114/wo.2012.28798.
Kowalski, D. M., Krzakowski, M., Ramlau, R., Jaskiewicz, P., & Janowicz-Żebrowska, A. (2012). Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Contemporary oncology (Poznan, Poland), 16(2), 170-5. https://doi.org/10.5114/wo.2012.28798
Kowalski, Dariusz M, et al. "Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland." Contemporary oncology (Poznan, Poland) vol. 16,2 (2012): 170-5. doi: https://doi.org/10.5114/wo.2012.28798
Kowalski DM, Krzakowski M, Ramlau R, Jaskiewicz P, Janowicz-Żebrowska A. Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Contemp Oncol (Pozn). 2012;16(2):170-5. doi: 10.5114/wo.2012.28798. Epub 2012 May 29. PMID: 23788872; PMCID: PMC3687401.
Copy Download .nbib Format: NLM
Potassium Complexes of Quercetin-5'-Sulfonic Acid and Neutral O-Donor Ligands: Synthesis, Crystal Structure, Thermal Analysis, Spectroscopic Characterization and Physicochemical Properties.

Materials (Basel, Switzerland)

Maciołek U, Mendyk E, Kosińska-Pezda M, Kamiński DM, Kozioł AE.
PMID: 34832203
Materials (Basel). 2021 Nov 11;14(22). doi: 10.3390/ma14226798.

The coordination ability of QSA

Cite
Maciołek U, Mendyk E, Kosińska-Pezda M, et al. Potassium Complexes of Quercetin-5'-Sulfonic Acid and Neutral O-Donor Ligands: Synthesis, Crystal Structure, Thermal Analysis, Spectroscopic Characterization and Physicochemical Properties. Materials (Basel). 2021;14(22)doi: 10.3390/ma14226798.
Maciołek, U., Mendyk, E., Kosińska-Pezda, M., Kamiński, D. M., & Kozioł, A. E. (2021). Potassium Complexes of Quercetin-5'-Sulfonic Acid and Neutral O-Donor Ligands: Synthesis, Crystal Structure, Thermal Analysis, Spectroscopic Characterization and Physicochemical Properties. Materials (Basel, Switzerland), 14(22), . https://doi.org/10.3390/ma14226798
Maciołek, Urszula, et al. "Potassium Complexes of Quercetin-5'-Sulfonic Acid and Neutral O-Donor Ligands: Synthesis, Crystal Structure, Thermal Analysis, Spectroscopic Characterization and Physicochemical Properties." Materials (Basel, Switzerland) vol. 14,22 (2021). doi: https://doi.org/10.3390/ma14226798
Maciołek U, Mendyk E, Kosińska-Pezda M, Kamiński DM, Kozioł AE. Potassium Complexes of Quercetin-5'-Sulfonic Acid and Neutral O-Donor Ligands: Synthesis, Crystal Structure, Thermal Analysis, Spectroscopic Characterization and Physicochemical Properties. Materials (Basel). 2021 Nov 11;14(22). doi: 10.3390/ma14226798. PMID: 34832203; PMCID: PMC8625810.
Copy Download .nbib Format: NLM
Isolation of Chitin from Black Soldier Fly (.

Polymers

Złotko K, Waśko A, Kamiński DM, Budziak-Wieczorek I, Bulak P, Bieganowski A.
PMID: 33800025
Polymers (Basel). 2021 Mar 07;13(5). doi: 10.3390/polym13050818.

Chitin has become a desirable raw material used in various areas of life. The black soldier fly (

Cite
Złotko K, Waśko A, Kamiński DM, et al. Isolation of Chitin from Black Soldier Fly (. Polymers (Basel). 2021;13(5)doi: 10.3390/polym13050818.
Złotko, K., Waśko, A., Kamiński, D. M., Budziak-Wieczorek, I., Bulak, P., & Bieganowski, A. (2021). Isolation of Chitin from Black Soldier Fly (. Polymers, 13(5), . https://doi.org/10.3390/polym13050818
Złotko, Katarzyna, et al. "Isolation of Chitin from Black Soldier Fly (." Polymers vol. 13,5 (2021). doi: https://doi.org/10.3390/polym13050818
Złotko K, Waśko A, Kamiński DM, Budziak-Wieczorek I, Bulak P, Bieganowski A. Isolation of Chitin from Black Soldier Fly (. Polymers (Basel). 2021 Mar 07;13(5). doi: 10.3390/polym13050818. PMID: 33800025; PMCID: PMC7962125.
Copy Download .nbib Format: NLM
Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials.

Journal of clinical medicine

Knetki-Wróblewska M, Kowalski DM, Krzakowski M.
PMID: 32708936
J Clin Med. 2020 Jul 17;9(7). doi: 10.3390/jcm9072273.

Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical...

Cite
Knetki-Wróblewska M, Kowalski DM, Krzakowski M. Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials. J Clin Med. 2020;9(7)doi: 10.3390/jcm9072273.
Knetki-Wróblewska, M., Kowalski, D. M., & Krzakowski, M. (2020). Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials. Journal of clinical medicine, 9(7), . https://doi.org/10.3390/jcm9072273
Knetki-Wróblewska, Magdalena, et al. "Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials." Journal of clinical medicine vol. 9,7 (2020). doi: https://doi.org/10.3390/jcm9072273
Knetki-Wróblewska M, Kowalski DM, Krzakowski M. Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials. J Clin Med. 2020 Jul 17;9(7). doi: 10.3390/jcm9072273. PMID: 32708936; PMCID: PMC7408765.
Copy Download .nbib Format: NLM
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare .

Oncology letters

Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, Powrózek T, Reszka K, Wojas-Krawczyk K, Bryl M, Wójcik-Superczyńska M, Głogowski M, Barinow-Wojewódzki A, Milanowski J, Krzakowski M.
PMID: 28599445
Oncol Lett. 2017 Jun;13(6):4433-4444. doi: 10.3892/ol.2017.5980. Epub 2017 Apr 03.

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of the

Cite
Krawczyk P, Kowalski DM, Ramlau R, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare . Oncol Lett. 2017;13(6):4433-4444doi: 10.3892/ol.2017.5980.
Krawczyk, P., Kowalski, D. M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., Wójcik-Superczyńska, M., Głogowski, M., Barinow-Wojewódzki, A., Milanowski, J., & Krzakowski, M. (2017). Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare . Oncology letters, 13(6), 4433-4444. https://doi.org/10.3892/ol.2017.5980
Krawczyk, Pawel, et al. "Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare ." Oncology letters vol. 13,6 (2017): 4433-4444. doi: https://doi.org/10.3892/ol.2017.5980
Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, Powrózek T, Reszka K, Wojas-Krawczyk K, Bryl M, Wójcik-Superczyńska M, Głogowski M, Barinow-Wojewódzki A, Milanowski J, Krzakowski M. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare . Oncol Lett. 2017 Jun;13(6):4433-4444. doi: 10.3892/ol.2017.5980. Epub 2017 Apr 03. PMID: 28599445; PMCID: PMC5453045.
Copy Download .nbib Format: NLM
Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot study.

Journal of contemporary brachytherapy

Lyczek J, Kazalski D, Kowalik L, Sawicki M.
PMID: 23349654
J Contemp Brachytherapy. 2012 Jun;4(2):113-5. doi: 10.5114/jcb.2012.29369. Epub 2012 Jun 30.

PURPOSE: Endobronchial brachytherapy (EB) is one way of treatment of patients with advanced lung cancer. Technological progress and the introduction of computed tomography for use in 3D planning allows one to define the area being treated very precisely, which...

Cite
Lyczek J, Kazalski D, Kowalik L, et al. Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot study. J Contemp Brachytherapy. 2012;4(2):113-5doi: 10.5114/jcb.2012.29369.
Lyczek, J., Kazalski, D., Kowalik, L., & Sawicki, M. (2012). Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot study. Journal of contemporary brachytherapy, 4(2), 113-5. https://doi.org/10.5114/jcb.2012.29369
Lyczek, Jarosław, et al. "Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot study." Journal of contemporary brachytherapy vol. 4,2 (2012): 113-5. doi: https://doi.org/10.5114/jcb.2012.29369
Lyczek J, Kazalski D, Kowalik L, Sawicki M. Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot study. J Contemp Brachytherapy. 2012 Jun;4(2):113-5. doi: 10.5114/jcb.2012.29369. Epub 2012 Jun 30. PMID: 23349654; PMCID: PMC3552634.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries